Drug intelligence / Profile preview

ABBV-623

Development stage: Discontinued
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

ABBV-623 is an orally bioavailable small molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), developed by AbbVie for the treatment of B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia. By binding to and inhibiting Bcl-2, ABBV-623 promotes apoptosis in malignant cells, exhibiting potential pro-apoptotic and antineoplastic activities. Clinical development included phase 1 trials as monotherapy and in combination with other agents for patients with relapsed or refractory B-cell cancers; however, development has been discontinued[1][2][3][4].

Targets

BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on ABBV-623.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-623.

Explore the full profile